Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.
about
Strategies to reduce hepatitis C virus recurrence after liver transplantationHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseHepatitis C and liver transplantationA thiopurine drug inhibits West Nile virus production in cell culture, but not in miceChallenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature.Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Treatment of hepatitis C virus infectionManagement of recurrent hepatitis C virus after liver transplantation.Liver transplantation for hepatitis C virus related liver diseaseLiving-donor liver transplantation and hepatitis CExpanded criteria donors.Therapeutic management of recurrent hepatitis C after liver transplantation.Risk factors for hepatitis C recurrence after liver transplantation.Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Histopathological evaluation of recurrent hepatitis C after liver transplantation: a reviewViral hepatitis and inflammatory bowel disease.Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation.Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressantsThe adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation.HCV in liver transplantation.Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience.Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.How does donor age influence the success of liver transplantation in patients with hepatitis?The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.Liver transplantation and hepatitis C
P2860
Q22305418-17505AD5-4311-4164-BE51-E40F17C6DE42Q26827444-FBF3B468-BEF0-403D-90EC-36B0AE9E0FA2Q27490388-B4E3B63B-ACB9-4193-BEC1-3DF750BCBC18Q28477601-BBE80D26-C242-4686-A123-20EDE096132AQ30244767-82576677-55C2-492B-89EE-0ABD39FE2E78Q33659942-472DD1E6-7272-44FF-93C3-A080F7309D2EQ34015754-8F598E3D-8A1D-4334-802D-3B993C19D4AEQ34093754-BC75444B-ACA4-42B5-8DDA-7A8A6F0BF1B4Q34099424-7B7A3414-D24A-4514-8055-CF7012DE308DQ34589655-5F093C46-F044-4070-84C0-BB10E71BEBA5Q36339458-EFC31038-405A-4317-BC89-008CEA63D901Q36587253-08D252B7-4461-437D-A2E7-60387C60D2D9Q36733650-DAC81652-4840-4217-AB44-2ADB79D3A1A8Q36758660-8B6186C1-4CC6-41D1-BF68-DBA0FAF11F39Q36980754-CF9F51AF-5968-4925-8926-B169180F75C9Q37317444-6425F296-A4B6-4BEB-A71C-2D8AE3A95646Q37654458-0FA483F6-BDFF-4CB2-80B7-E1EA4048999AQ37756044-C9D4554D-3D6E-4055-9704-FC2170D495B6Q37973516-38390E20-BED9-41D8-BD0B-20CF50B32950Q38011694-36EFB666-BB77-41D1-8B2F-AAEF1F000ED0Q38057373-E12B306E-93A5-472F-B6C8-0F648FAF53FBQ39968802-38FCE804-8EEF-4D59-B463-9E2C81C2D053Q40679311-70BA958B-CF6D-46B5-8352-9598D3614A37Q42028499-29856D8D-C4E3-4B44-B3B6-F0C55E3D046EQ42982631-70E21296-E224-4D8B-991D-8F2B2F153ACCQ43001526-36353629-D420-4E32-9F04-9288A26EEDC5Q45358749-F34EE425-F19D-4A3D-AFC0-E4072B0D5A5EQ45417494-BB1312AC-B2FC-4737-9F5A-18CF0648AE95Q52936013-473650EA-2D22-4773-831C-0C24CBE78356Q55692477-ED16028C-E990-49C8-AA39-DE509C420EE4Q58704499-470DE5A7-B309-4CF6-BC40-39ED1C0D2534
P2860
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Immunosuppression and donor ag ...... e after liver transplantation.
@en
Immunosuppression and donor ag ...... e after liver transplantation.
@nl
type
label
Immunosuppression and donor ag ...... e after liver transplantation.
@en
Immunosuppression and donor ag ...... e after liver transplantation.
@nl
prefLabel
Immunosuppression and donor ag ...... e after liver transplantation.
@en
Immunosuppression and donor ag ...... e after liver transplantation.
@nl
P2093
P50
P356
P1476
Immunosuppression and donor ag ...... e after liver transplantation.
@en
P2093
Alberto Quaglia
Amar P Dhillon
Brian R Davidson
Christos K Triantos
David W Patch
Dimitrios N Samonakis
Keith Rolles
Nancy Rolando
Paul Griffiths
Rosângela Teixeira
P304
P356
10.1002/LT.20344
P50
P577
2005-04-01T00:00:00Z